Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.

Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Studničkova 2 12800 Prague 2 Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady 10034 Prague Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Thomayer University Hospital Prague Czech Republic

Department of Pathology Bulovka Hospital Prague Czech Republic

Department of Pathology Faculty of Medicine University of Debrecen 4032 Debrecen Hungary

Department of Pathology University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic

Šikl's Department of Pathology The Faculty of Medicine and Faculty Hospital in Pilsen Charles University Pilsen Czech Republic

The Fingerland Department of Pathology Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové Hradec Králové Czech Republic

Zobrazit více v PubMed

Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22–32. https://doi.org/10.1034/j.1600-065x.2002.18803.x PubMed DOI

Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2):199–208. https://doi.org/10.1016/s1074-7613(00)80426-4 PubMed DOI

Caballero OL, Chen Y-T (2009) Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 100:2014–2021. https://doi.org/10.1111/j.1349-7006.2009.01303.x PubMed DOI

Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q (2014) Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2(4):371–379. https://doi.org/10.1158/2326-6066.CIR-13-0088 PubMed DOI

Li J, Yin J, Zhong J, Yang Z, Tang A, Li S (2020) Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis. Biomed Res Int 2020:8828579. https://doi.org/10.1155/2020/8828579 PubMed DOI PMC

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102(17):6092–6097. https://doi.org/10.1073/pnas.0501564102 PubMed DOI PMC

Mirjam T (2006) Epping, René Bernards; A Causal Role for the Human Tumor Antigen Preferentially Expressed Antigen of Melanoma in Cancer. Cancer Res 66(22):10639–10642. https://doi.org/10.1158/0008-5472.CAN-06-2522 DOI

Neumann E, Engelsberg A, Decker J, Störkel S, Jaeger E, Huber C, Seliger B (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 58(18):4090–4095 PubMed

Bankovic J, Stojsic J, Jovanovic D, Andjelkovic T, Milinkovic V, Ruzdijic S, Tanic N (2010) Identification of genes associated with non-small-cell lung cancer promotion and progression. Lung Cancer 67(2):151–159. https://doi.org/10.1016/j.lungcan.2009.04.010 PubMed DOI

Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M (2004) The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10(13):4307–4313. https://doi.org/10.1158/1078-0432.CCR-03-0813 PubMed DOI

Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O’Driscoll L (2008) Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat 109(2):359–365. https://doi.org/10.1007/s10549-007-9643-3 PubMed DOI

Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP (2017) Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11. https://doi.org/10.1186/s13569-017-0077-3 PubMed DOI PMC

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ (2017) PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmol 135(6):541–549. https://doi.org/10.1001/jamaophthalmol.2017.0729 PubMed DOI PMC

Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M (2008) The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica 93(12):1797–1805. https://doi.org/10.3324/haematol.13214 PubMed DOI

Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B (2002) Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133(2):118–123. https://doi.org/10.1016/s0165-4608(01)00570-2 PubMed DOI

Abdelmalak CA, Yahya RS, Elghannam DM, El-Khadragy AE, Abd-El-Messih HM (2014) PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis. Clin Lab 60(1):55–61. https://doi.org/10.7754/clin.lab.2013.121137 PubMed DOI

Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP (2007) Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 46(9):796–804. https://doi.org/10.1002/gcc.20465 PubMed DOI

Lee YK, Park UH, Kim EJ, Hwang JT, Jeong JC, Um SJ (2017) Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. Cancer Lett 403:144–151. https://doi.org/10.1016/j.canlet.2017.06.015 PubMed DOI

Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, Tsunoda K, Ishikawa Y, Watanabe A, Takahashi K, Akasaka T, Masuda T (2011) Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol 39(3):665–672. https://doi.org/10.3892/ijo.2011.1084 PubMed DOI

Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ (2018) PRAME Expression in Melanocytic Tumors. Am J Surg Pathol 42(11):1456–1465. https://doi.org/10.1097/PAS.0000000000001134 PubMed DOI PMC

Lezcano C, Müller AM, Frosina D, Hernandez E, Geronimo JA, Busam KJ, Jungbluth AA (2021) Immunohistochemical Detection of Cancer-Testis Antigen PRAME. Int J Surg Pathol 29(8):826–835. https://doi.org/10.1177/10668969211012085 PubMed DOI

Kaczorowski M, Chłopek M, Kruczak A, Ryś J, Lasota J, Miettinen M (2022) PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors. Am J Surg Pathol. 46(11):1467–1476. https://doi.org/10.1097/PAS.0000000000001944 PubMed DOI

Dundr P, Bazalová B, Bártů M, Bosse T, Drozenová J, Fabian P, Fadare O, Hausnerová J, Jakša R, Laco J, Lax SF, Matěj R, McCluggage WG, Méhes G, Michálková R, Němejcová K, Singh N, Stolnicu S, Škapa P, Švajdler M, Stružinská I (2022) The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Arch 481(2):201–212. https://doi.org/10.1007/s00428-022-03338-z PubMed DOI

Kunc M, Żemierowska N, Skowronek F, Biernat W (2023) Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions. Histopathology 83(1):3–14. https://doi.org/10.1111/his.14904 PubMed DOI

Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A (2011) A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother 34(7):556–567. https://doi.org/10.1097/CJI.0b013e3182280db1 PubMed DOI PMC

Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo P, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhoutte N, Salaun B, Gillet M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF (2016) Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open 1(4):e000068. https://doi.org/10.1136/esmoopen-2016-000068 PubMed DOI PMC

Al-Khadairi G, Decock J (2019) Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? Cancers (Basel) 11(7):984. https://doi.org/10.3390/cancers11070984 PubMed DOI

Naik A, Thomas R, Al-Khadairi G, Bacha R, Hendrickx W, Decock J (2021) Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential. J Cell Mol Med 25(22):10376–10388. https://doi.org/10.1111/jcmm.16967 PubMed DOI PMC

Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR (2016) PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget 7(29):45352–45369. https://doi.org/10.18632/oncotarget.9977 PubMed DOI PMC

Brenne K, Nymoen DA, Reich R, Davidson B (2012) PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am J Clin Pathol 137(2):240–247. https://doi.org/10.1309/AJCPGA95KVSAUDMF PubMed DOI

Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G (2008) Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer 123(9):2130–2137. https://doi.org/10.1002/ijc.23758 PubMed DOI

Coppock JD, Gradecki SE, Mills AM (2023) PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall. Int J Gynecol Pathol 42(1):35–42. https://doi.org/10.1097/PGP.0000000000000864 PubMed DOI

Němejcová K, Šafanda A, Bártů MK, Michálková R, Drozenová J, Fabian P, Hausnerová J, Laco J, Matěj R, Méhes G, Škapa P, Stružinská I, Dundr P (2023) A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. Diagn Pathol 18(1):32. https://doi.org/10.1186/s13000-023-01317-9 PubMed DOI PMC

Dundr P, Bártů M, Bosse T, Bui QH, Cibula D, Drozenová J, Fabian P, Fadare O, Hausnerová J, Hojný J, Hájková N, Jakša R, Laco J, Lax SF, Matěj R, Méhes G, Michálková R, Šafanda A, Němejcová K, Singh N, Stolnicu S, Švajdler M, Zima T, Stružinská I, McCluggage WG (2023) Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories. Mod Pathol 36(1):100040. https://doi.org/10.1016/j.modpat.2022.100040 PubMed DOI